RxDoctor Payments Data

Mark Dyer, MD

Internal Medicine · Little Rock, ARNPI 1114085768

Payments from drug & device makers

$526in general payments, 2019–2025

Across 29 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$93
  • Shield Therapeutics Inc$90
  • Lilly USA, LLC$76
  • AbbVie$74
  • GSK$43
  • Antares Pharma, Inc.$38
  • plus $111 from 5 others

What the payments were for

  • Food & beverage$526100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$526 in reported general payments places this provider in the 65th percentile of 614 internal medicine providers in Arkansas.

See all internal medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$406,776
Medicare patients
513
Services billed
15,159

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide170$167,499
EliquisApixaban71$57,334
TrulicityDulaglutide60$54,943
MounjaroTirzepatide35$48,565
MyrbetriqMirabegron69$40,827
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)11$10,394
Breo ElliptaFluticasone/Vilanterol27$10,121
JardianceEmpagliflozin12$7,212
Potassium Chloride235$6,588
SynthroidLevothyroxine Sodium88$6,133
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$5,644
XareltoRivaroxaban12$5,258
Levothyroxine Sodium423$4,955
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$4,189
Escitalopram Oxalate316$3,544

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$93$167,499170 claims
Lilly USA, LLCTrulicity, Mounjaro$76$103,50895 claims
PfizerEliquis$21$57,33471 claims
GSKBreo Ellipta$43$10,12127 claims
AbbVieSynthroid$74$6,13388 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 614 internal medicine providers in Arkansas.

Other internal medicine in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →